Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;1(2):345-349.
doi: 10.3892/ol_00000061. Epub 2010 Mar 1.

Chemosensitivity of lung cancer: Differences between the primary lesion and lymph node metastasis

Affiliations

Chemosensitivity of lung cancer: Differences between the primary lesion and lymph node metastasis

Yoshimasa Maniwa et al. Oncol Lett. 2010 Mar.

Abstract

In this study, chemosensitivity tests were performed on both primary lesions (PLs) and lymph node metastases (LMs) from surgically resected non-small cell lung cancer (NSCLC). Differences between the results obtained were evaluated. Operative specimens were obtained from 13 patients with NSCLC [6 with squamous cell carcinoma (SQ) and 7 with adenocarcinoma (AD)] whose lymph nodes were confirmed to be positive for metastasis. Both the PL and LM from the same patient were examined immediately after resection. The collagen gel droplet-embedded culture drug sensitivity test (CD-DST) was used as the chemosensitivity test against six anticancer drugs [5-fluorouracil (5-FU), cisplatin, gemcitabine, docetaxel, vinorelbine and SN-38 (an active metabolite of irinotecan)]. When the growth rate, determined by the T/C ratio (T, signal for viable cells in the treated group and C, signal in the control) was less than 50%, the tumor cells were considered to be sensitive to the drug. Only in 4 cases (2 SQ and 2 AD) was the chemosensitivity of the primary lesion identical to that of LM. In the SQ cases, chemosensitivity of the primary lesions to 5-FU tended to be consistent with that of LMs. In contrast, the primary lesions in 4 of the 7 AD cases were negative for chemosensitivity to 5-FU; however, LMs were sensitive. In many cases, the chemosensitivity of the PLs to each anticancer drug differed from that of the LMs. In conclusion, both primary and metastatic tumors should be examined to ensure maximum clinical efficacy of in vitro drug-sensitivity testing for adjuvant chemotherapy after complete resection of n1 and n2 NSCLC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemosensitivity against 5-fluorouracil. In adenocarcinoma (AD), the number of lymph node metastases (LMs) that were assessed as positive was much higher than the number of primary lesions (PLs). SQ, squamous cell carcinoma.
Figure 2
Figure 2
Proliferation rate against 5-fluorouracil (5-FU). In the adenocarcinoma (AD) cases, the T/C percentage of the lymph node metastases (LMs) was significantly lower than that of the primary lesions (PLs). Consequently, the LMs were more sensitive to 5-FU than the PLs. SQ, squamous cell carcinoma.

Similar articles

Cited by

References

    1. Freeman AE, Hoffman RM. In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA. 1986;83:2694–2698. - PMC - PubMed
    1. Cole SP. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol. 1986;17:259–263. - PubMed
    1. Kobayashi H, Tanisaka K, Doi O, et al. An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol. 1997;11:449–455. - PubMed
    1. Shaw GL, Gazdar AF, Phelps R, et al. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res. 1993;53:5181–5187. - PubMed
    1. Gazdar AF, Steinberg SM, Russell EK, et al. Correlation of in vitro drug-sensitivity testing with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst. 1990;82:117–124. - PubMed

LinkOut - more resources